Market Data 
Markets
Replies to post #171801 on Anavex Life Sciences Corp (AVXL)
Dr. Hachiro Sugimoto
Born in 1942. Joined Eisai in 1961. Leader of E2020 (Aricept) project team at Brain and Nerve Unit Chemistry Group, Tsukuba Research Laboratories (TRL) from 1983. Aricept creators representative. Previous positions in Eisai include Director of Discovery Research Laboratory I. Professor at Graduate School of Pharmaceutical Sciences, Kyoto University in 2003. Currently conducting further research on Alzheimer's disease as Chair Professor of Center for Neurologic Disease, Graduate School of Brain Science, Doshisha University. Current chairman of venture business PharmaEight Co., Ltd.
My mother suffered from dementia.
What was the motivation behind your commitment to develop a treatment for Alzheimer's disease?
Dr. Sugimoto : My mother developed dementia in her later years. Whenever I went to visit her, she'd ask me, “Young man, who are you?” It was a shock to me that my mother could no longer recognize her own son. I would say to her, “Mom, it's me, your son Hachiro,” and she'd reply, “Oh, you don't say? My son's name is Hachiro. You both have the same name.” It was a very sad time for me and I found it difficult to accept the reality of the situation. With these memories of my mother playing in my mind, I felt inspired that it was my mission as a scientist to generate an effective new drug for Alzheimer's, despite the illness' notoriety for being one of the most difficult-to-treat diseases.
AI
